Health Winners & Losers: Indevus
Updated from 4:19 p.m. EDT
Health stocks stayed in positive territory overall on Friday with a few regulatory and deal-oriented headlines.
One big mover, Indevus (IDEV), rocketed $1.78, or 103%, to $3.51 on a double dose of positive news.
Indevus said Friday that it will resubmit its application for its testosterone replacement therapy, Nebido, in the first quarter of 2009 and that a new trial -- which could have delayed the filing for up to 18 months -- won't be necessary. Separately, the company announced it will partner with Teva Pharmaceuticals (TEVA) for pagaclone, a drug for treating stuttering that's in midstage development.Heading in the other direction, NPS Pharmaceuticals (NPSP) said in a filing with the Securities and Exchange Commission on Thursday that GlaxoSmithKline (GSK) is terminating a phase II study of osteoporosis drug Ronacaleret due to lack of efficacy. Shares gave up $1.05, or 12.6%, to $7.28 on Friday. Also on the decline, Savient Pharmaceuticals' (SVNT) shares fell after the company said that it is still evaluating its options for its lead product, pegloticase, as well as other transactions to maximize shareholder value. The company said, however, that it can't give any assurance if or when a deal will get done. The company said it was on track to file its application for the approval of the drug with the FDA by the end of October. Shares declined $2.90, or 15.5%, to $15.82. In other news, Alpharma (ALO) hasn't tired of rejecting King Pharmaceuticals (KG). The company advised shareholders not to tender their shares to King. Earlier in September, King's board authorized a tender offer to purchase all of the outstanding shares of Class A Common Stock of Alpharma for $37 a share -- up from its initial $33 a share proposal.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV